IBM and Summit Therapeutics Shares Surge Post-Market on Tech and Clinical Breakthroughs

Key Facts

In a move reflecting the accelerating tech race on Wall Street, post-market trading saw significant rallies in both mega-cap and biotech stocks. According to reports, IBM shares surged nearly 7% driven by investor optimism regarding the company's quantum computing ventures and positive commentary from Donald Trump. Simultaneously, Summit Therapeutics shares rose over 10% following the announcement of positive Phase 3 clinical trial data for Ivonescimab, which demonstrated a survival advantage in lung cancer patients.

IBM's rally comes amid a massive $10 billion investment in quantum computing technology, positioning it as a key challenger to peers like Microsoft and Google. For Summit Therapeutics, the success of its drug represents a potential challenge to established cancer treatments from companies such as Merck (MRK), as clinical data showed superior efficacy. Per market data, this momentum reflects growing retail and institutional confidence in disruptive innovations across both the computing and healthcare sectors.

Looking ahead at the economic calendar, the market awaits the CB Consumer Confidence report on May 26, followed by US GDP Growth Rate data on May 28, both of which could influence broader risk appetite in the technology and healthcare sectors.